Inhibrx amends grant of 10,000 options to director

Director Kristiina Vuori, MD was granted 10,000 stock options in an amended Form 4 correcting an earlier administrative error.

Available on EDGAR 09/18/2026 - 04:26 PM EDT Accepted by SEC EDGAR 09/18/2026 - 04:25 PM EDT Learn about SEC filing dates

This filing corrects an earlier one, and you can read the original Form 4 if you want to see what changed.

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. (INBX) reports that director Kristiina Vuori, MD received a grant of 10,000 stock options on June 3, 2026, each with an exercise price of $95.22 and expiring on June 3, 2036. The option becomes fully exercisable on June 3, 2027, subject to her continued service, and this amended filing corrects the original option amount reported.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Vuori Kristiina MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Key Figures

Stock options granted: 10,000 options Exercise price: $95.22 per share Options held after grant: 10,000 options +2 more

5 metrics

Stock options granted 10,000 options Grant to director Kristiina Vuori, MD on June 3, 2026

Exercise price $95.22 per share Exercise price of the stock options granted June 3, 2026

Options held after grant 10,000 options Total stock options held directly after the reported transaction

Vesting date June 3, 2027 Date the stock option becomes fully exercisable, subject to continued service

Expiration date June 3, 2036 Option expiration for the granted stock options

Key Terms

Amended Form 4, stock option, fully exercisable, administrative error

4 terms

Amended Form 4 regulatory

"This Amended Form 4 restates the original Form 4 filed on June 4, 2026"

stock option financial

"This stock option will be fully exercisable on June 3, 2027"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

fully exercisable financial

"This stock option will be fully exercisable on June 3, 2027"

administrative error other

"to correct the number of options granted to the Reporting Person due to an administrative error"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INBX report for director Kristiina Vuori, MD?

The company reported a grant of 10,000 stock options to director Kristiina Vuori, MD on June 3, 2026, with an exercise price of $95.22 per share and an expiration date of June 3, 2036.

Why was this Form 4 for INBX filed as an amendment?

It was filed as an amendment to correct the number of options granted to the reporting person, which had been misstated in the original Form 4 due to an administrative error.

When do the INBX stock options granted to Kristiina Vuori become exercisable?

The filing states that this stock option will be fully exercisable on June 3, 2027, provided that the reporting person continues in service through that date.

What is the exercise price and term of the INBX stock options granted?

The stock options have an exercise price of $95.22 per share and an expiration date of June 3, 2036, giving a ten-year term from the June 3, 2026 grant date.

How many INBX options does the reporting person hold after this transaction?

After this reported grant, the filing shows the reporting person holding 10,000 stock options directly, corresponding to the options reported in this transaction.

Were the INBX option transactions made under a Rule 10b5-1 trading plan?

The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this stock option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vuori Kristiina MD

(Last) (First) (Middle)

C/O INHIBRX BIOSCIENCES, INC.

11025 N. TORREY PINES ROAD, SUITE 140

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/04/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$95.22	06/03/2026		A		10,000		06/03/2027(1)	06/03/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Remarks:

This Amended Form 4 restates the original Form 4 filed on June 4, 2026 in its entirety to correct the number of options granted to the Reporting Person due to an administrative error.

	/s/ Kelly Deck, as attorney-in-fact to Kristiina Vuori	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)